Market Overview

Vetr Crowd Upgrades Valeant


The Vetr community has upgraded Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from 3 stars to 3.5 stars.

The crowd is overall much more bearish on the name than Wall Street, with a price target of $14.26 compared to analyst consensus $24.58.

See how crowdsourced ratings can help predict the market?

Valeant shares closed at $12.92 Monday.

For the crowd's full analysis of the stock, click here.

Latest Ratings for VRX

Jun 2018DowngradesBuyHold
Jun 2018UpgradesEqual-WeightOverweight
May 2018UpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Crowdsourcing Analyst Ratings General


Related Articles (VRX)

View Comments and Join the Discussion!

Latest Ratings

NXTCBank of AmericaReiterates89.0
RNRJP MorganAssumes173.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Vetr Urges Buy On Antares Post-Correction

Wall Street's M&A Chatter From October 16: Ruby Tuesday, Nordstrom, Aramark-Avendra, Impax-Amneal